FePt NPs offer not only the advantages of dual imaging in CT and MRI but also enhance radiotherapy sensitivity. Our team has discovered that utilizing FePt NPs as carriers for small molecule inhibitors can significantly improve the therapeutic effects on cancer cells. It has been revealed that the novel iron-platinum nanocomplex FFP has the potential to revolutionize nano-radioimmunotherapy. This advancement holds significant promise for cancer treatment and benefits a wide range of patients.

FTY720 can enhance the dispersion of NPs in the liquid phase, reducing the use of adjuvants and interference with relevant signal pathways. TPGS stabilizes FFP and minimizes damage to normal tissues. Additionally, inhibition of P-gp activity increased drug concentration to facilitate cell death. Dual imaging capabilities in CT/MRI make FFP one of a kind in the market. Core technology empowers FFP with theranostic functionality providing a comprehensive and highly effective treatment strategy.

Due to CT/MRI dual-contrast imaging capabilities, FePt NPs can initially target the imaging market with more lenient regulations. Approach ensures early profitability and gradual market share expansion. Later, enter the radiotherapy market, leveraging the advantages of minimizing side effects and enhancing patients＇ quality of life, differentiating from competitors. Integrating novel drug strategies as theranostics to stimulate market demand and supply, resulting in an expanded market presence.